Fox Run Management, L.L.C. Ultragenyx Pharmaceutical Inc. Transaction History

Fox Run Management, L.L.C.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$37.35 - $52.15 $182,529 - $254,857	4,887 New	4,887 $225,000
Q3 2022 Nov 07, 2022	BUY	$39.96 - $66.14 $533,665 - $883,299	13,355 New	13,355 $553,000
Q2 2022 Aug 12, 2022	SELL	$45.8 - $85.4 $246,953 - $460,476	-5,392 Closed	0 $0
Q1 2022 May 10, 2022	BUY	$62.2 - $84.4 $335,382 - $455,084	5,392 New	5,392 $392,000
Q3 2021 Nov 15, 2021	SELL	$77.92 - $102.4 $417,962 - $549,273	-5,364 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$92.19 - $115.71 $198,208 - $248,776	2,150 Added 66.89%	5,364 $511,000
Q2 2019 Jul 17, 2019	BUY	$54.93 - $74.36 $176,545 - $238,993	3,214 New	3,214 $204,000
Q1 2018 Apr 17, 2018	SELL	$44.33 - $58.52 $507,711 - $670,229	-11,453 Closed	0 $0
Q4 2017 Jan 18, 2018	BUY	$43.54 - $57.32 $324,503 - $427,205	7,453 Added 186.33%	11,453 $531,000
Q3 2017 Oct 23, 2017	BUY	$49.79 - $66.32 $199,160 - $265,280	4,000	4,000 $213,000

325

85.5M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.14B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.